NEW YORK, April 2, 2015 – Replicor Inc., a
privately held biopharmaceutical company targeting a cure for chronic
hepatitis B and D patients, today announced the completion of enrollment
in its latest phase II proof of concept trial (REP 301 protocol). This
trial will examine the safety and efficacy of combined REP 2139-Ca and
Pegasys® (peginteferon alfa-2a) treatment in patients with chronic
hepatitis B / hepatitis D co-infection.
The REP 301 protocol (
NCT02233075)
is examining the safety and efficacy of REP 2139-Ca monotherapy
followed by combination therapy with REP 2139-Ca and Pegasys® in
patients with chronic hepatitis B / hepatitis D co-infection. This proof
of concept trial is designed to achieve the following milestones:
1. Demonstrate the safety of REP 2139-Ca in monotherapy and when combined with Pegasys® in Caucasian patients.
2. Confirm the pharmacological effect of REP 2139-Ca (HBsAg release
inhibition) observed in previous Asian trials (REP 102 and 201
protocols) in Caucasian patients.
3. Demonstrate combined antiviral efficacy against both hepatitis B and hepatitis D infections.
4. Assess SVR rates achievable with REP 2139-Ca / Pegasys® combination therapy.
Source:
http://replicor.com/replicor-announces-completion-enrollment-phase-ii-trial/